Healthy Skepticism Library item: 18025

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Ault A
Drugs & devices
Lancet 1998 Mar 28; 351:(9107):968
http://www.lancet.com/journals/lancet/article/PIIS0140-6736(05)60639-3/fulltext

Abstract:

Vancomycin alternative A US FDA advisory panel recommended approval of the first alternative to vancomycin in 30 years, the injectable streptogramin quin-upristin/dalfopristin (Synercid). Rhone-Poulenc Rorer hoped to get backing for its use against various drug-resistant organisms. Instead, the panel backed approval by indication: for complicated skin and skin-structure infections and nosocomial pneumonia, but not for community-acquired pneumonia. Synercid was also recommended for vancomycin-resi …